PHAXIAM Therapeutics
A biopharmaceutical company, develops enzyme-based medicinal products for the oncology, hematology and immunology sectors.
Launch date
Employees
Market cap
$18.1m
Enterprise valuation
$26m (Public information from Sep 2024)
Share price
$0.5431 ERYP
Company register number 479560013
Lyon Auvergne-Rhône-Alpes (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 4.0m | 4.0m | 31.0m | 47.0m | 1.1m | 1.6m | - |
| % growth | (20 %) | - | 675 % | 52 % | (98 %) | 52 % | - |
| EBITDA | (64.0m) | (51.0m) | 2.0m | (25.3m) | (17.5m) | (18.0m) | (18.5m) |
| % EBITDA margin | (1600 %) | (1275 %) | 6 % | (54 %) | (1667 %) | (1125 %) | - |
| Profit | (73.0m) | (54.0m) | (<1m) | (23.5m) | (17.3m) | (19.7m) | (19.2m) |
| % profit margin | (1825 %) | (1350 %) | (1 %) | (50 %) | (1648 %) | (1234 %) | - |
| EV / revenue | 30.5x | 14.4x | -0.5x | 0.6x | 22.6x | 20.2x | - |
| EV / EBITDA | -1.9x | -1.1x | -6.9x | -1.1x | -1.4x | -1.8x | -1.2x |
| R&D budget | 59.8m | 48.5m | 19.1m | - | - | - | - |
| R&D % of revenue | 1494 % | 1213 % | 62 % | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€750k | Series A | ||
€12.0m | Early VC | ||
€5.0m | Series B | ||
€4.0m | Series C | ||
| N/A | €17.3m Valuation: €63.8m | IPO | |
| N/A | €30.0m | Post IPO Equity | |
| N/A | €25.4m | Post IPO Equity | |
| N/A | €70.5m | Growth Equity VC | |
| N/A | N/A | IPO | |
N/A | Post IPO Equity | ||
€10.0m | Post IPO Debt | ||
| N/A | $30.0m | Post IPO Equity | |
* | N/A | Merger | |
* | €7.8m | Post IPO Equity | |
| Total Funding | $101m | ||
Related Content
Recent News about PHAXIAM Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by PHAXIAM Therapeutics
Edit
exited